Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.9652W HIGH $8.00
Volume
15.03 K
Value Traded
186.59 K
Short % Float
3.98%
-19.48%Week
-14.73%1 Month
-9.39%3 Month
-7.64%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.16 M
EPS (TTM)
-3.94
P/E Ratio
-
Ent. Value
5.42 M
Total Shares
1.50 M
Float Shares
710.00 K
Insiders
52.62%
Institutions
10.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NDRA Catalyst Timeline
Dated clinical, regulatory and corporate events for ENDRA Life Sciences Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ENDRA Life Sciences Inc.
2Total events
0Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How NDRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
ENDRA Life Sciences Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NDRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TAEUS Liver | steatotic liver disease | 2025-12-04 | critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%; high Positive Predictive Value (PPV); high Negative Predictive Value (NPV); 40 subjects with BMI ranging from 21 to 47; less than $200Read More | ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial UseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| UBS Group AG10% Owner | Buy | 3,715 146,012 held | $0.55 | 08/27/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in NDRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NDRA for Q2 2026. | ||||
NDRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NDRA ranks across every disease it competes in
Competitive Position is a premium feature
See how NDRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNDRA News
NDRAENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. reported its financial results for Q2 2026, highlighting a strategic merger with ASP Isotopes Inc. The company continues to innovate in thermoacoustic biomarker imaging, focusing on early detection of steatotic liver disease. This merger is expected to enhance ENDRA's market position and operational capabilities.
Read more →NDRA▼ -8.9%on this news
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes has announced a proposed merger of Noble Africa with ENDRA Life Sciences, alongside a concurrent private placement financing of approximately $50 million. This merger aims to enhance the capabilities and market presence of both companies. Further details on the merger's implications and the financing structure have yet to be disclosed.
Read more →NDRA▲ +7.1%on this news
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences has reported its financial results for the first quarter of 2026. The company also provided a business update, although specific details about the results or updates were not disclosed in the article. The overall sentiment remains neutral due to the lack of detailed information.
Read more →NDRAENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
ENDRA Life Sciences has reported successful multi-site validation of its TAEUS® liver device, showcasing MRI-like accuracy and reproducibility in liver imaging. This validation is a significant step forward for the company, enhancing the credibility of the device in clinical settings. The results indicate a promising future for the TAEUS® technology in liver diagnostics.
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ENDRA Life Sciences reported its financial results for Q4 and full year 2025, highlighting significant clinical advancements with its TAEUS Liver technology. The company has initiated a review of strategic alternatives to enhance shareholder value while maintaining focus on its operational initiatives. Despite a reduction in operating expenses, ENDRA continues to face net losses, raising concerns about its financial sustainability.
Read more →NDRA▲ +8.4%on this news· ran to +35% by day 3
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ENDRA Life Sciences has begun evaluating strategic alternatives to maximize shareholder value. The Board of Directors is considering various options, including mergers and collaborations, while continuing to focus on its operational initiatives. The company has engaged financial and legal advisors to assist in this process, although no specific timeline has been set for its completion.
Read more →NDRAENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
ENDRA Life Sciences announced positive results from a clinical study of its TAEUS Liver device, demonstrating high consistency in measurements crucial for monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The device achieved a high reliability score, indicating its potential to deliver MRI-level results at a lower cost, which is vital for clinicians and pharmaceutical companies. This innovation could significantly improve patient care and monitoring.
Read more →NDRA▼ -7.7%on this news
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
ENDRA Life Sciences announced promising results from its TAEUS Liver device feasibility study, demonstrating that its thermo-acoustic fat fraction measurement closely aligns with the MRI-PDFF standard at critical liver fat thresholds. This positions TAEUS as a low-cost, effective tool for monitoring steatotic liver disease, potentially transforming the landscape for MASLD/MASH drug development. The study highlights TAEUS's ability to identify patients for clinical trials and therapy decisions efficiently.
Read more →NDRA▼ -5.9%on this news
ENDRA Life Sciences Closes Up to $14.4 Million Private
ENDRA Life Sciences Inc. has closed a private placement worth up to $14.4 million, which includes an initial $4.9 million and potential future proceeds from warrant exercises. Concurrently, the company launched its digital asset treasury strategy, investing $3 million in HYPE tokens. This strategy aims to enhance shareholder value through active yield-enhancement techniques in decentralized finance (DeFi). Despite the optimistic outlook, the company faces risks, including regulatory uncertainties and limited experience in the cryptocurrency sector.
Read more →NDRARecent Financial Results Below is a summary of certain preliminary estimates regarding our financial results for the quarter ended
The preliminary financial results for NDRA indicate a challenging quarter ending June 30, 2025. The company expects no revenue for this quarter, similar to the previous year. Although the loss from operations has decreased to approximately $1.3 million from $2.2 million, the total assets and working capital remain low, raising concerns about financial sustainability.
Read more →NDRAENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results
ENDRA Life Sciences recently provided a business update along with its first quarter 2025 financial results. The company is pivoting towards addressing metabolic diseases, specifically through the development of a low-cost, point-of-care diagnostic device for liver fat detection. Within its new strategy, ENDRA aims to improve early diagnosis, reduce healthcare costs, and has also reported a significant reduction in its operating expenses. However, the company faces challenges related to regulatory compliance and capital acquisition for continued operations.
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences reported its financial results for the fourth quarter and full year 2024, highlighting significant advances in the development of its TAEUS Liver device. The company refocused its strategies to improve regulatory processes and commenced a new multicenter clinical study involving major evaluation sites. Despite increased operating expenses and a higher net loss compared to 2023 due to one-time charges, ENDRA achieved notable reductions in cash burn through operational efficiencies. The revamped regulatory strategy is aimed at supporting a successful De Novo submission to the FDA.
Read more →NDRAENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement ANN ARBOR, Mich. (
ENDRA Life Sciences has announced that it has regained compliance with the Nasdaq minimum bid price requirement, as confirmed by the Nasdaq Listing Qualifications Department. The compliance allows ENDRA to focus on its transformational business strategies, which were discussed in a recent conference call. The company is known for its innovative technology, Thermo Acoustic Enhanced UltraSound (TAEUS), aimed at addressing the challenges related to assessing liver fat content and monitoring liver diseases.
Read more →NDRA▼ -14.2%on this news
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update Company accelerated enrollment in global multisite pilot study and significantly reduced operating expenses while refocusing
ENDRA Life Sciences reported its third quarter financial results, highlighting key developments in its Thermo Acoustic Enhanced UltraSound (TAEUS) technology. The company successfully accelerated subject recruitment for ongoing clinical evaluations and significantly lowered operating expenses by 54%. New AI-driven features for the TAEUS platform were developed, and the company expanded its intellectual property portfolio. Despite a net loss of $2.4 million in the quarter, the company remains focused on generating clinical data to support its FDA regulatory filing efforts.
Read more →NDRA▼ -19.6%on this news· ran to -32% by day 3
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. received an extension from Nasdaq until November 20, 2024, to comply with a minimum bid price requirement necessary for continued listing. The company needs to demonstrate a closing bid price of at least $1.00 per share for 10 consecutive trading days. The extension comes amid significant activity, as 91% of Series B Warrants have been exercised recently. ENDRA's TAEUS technology is recognized for its potential in non-invasive tissue assessment, particularly for fatty liver disease.
Read more →NDRAENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. reported its financial results for the second quarter of 2024, highlighting significant advancements in regulatory and clinical activities. The company successfully met with the FDA to discuss the TAEUS technology and initiated pilot clinical trials in North America and Europe. Additionally, ENDRA expanded its intellectual property portfolio, adding five new patents. Financially, the company raised $8 million through a public offering and reduced operating expenses by $3.1 million compared to the previous year.
Read more →NDRA▼ -22.5%on this news· ran to -83% by day 3
ENDRA Life Sciences Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on
ENDRA Life Sciences has announced a 1-for-50 reverse stock split, effective August 20, 2024, to comply with Nasdaq's minimum bid price requirements. As a result, the number of outstanding shares will decrease significantly from approximately 72.4 million to about 1.4 million. The split is intended to stabilize the stock price and help the company maintain its Nasdaq listing. Stockholders will automatically have their shares adjusted without needing to take further action, and details about the split can be found in the company's regulatory filings.
Read more →NDRAENDRA Life Sciences Announces Leadership Changes Board Member Alexander Tokman appointed as acting CEO bringing 24+ years of global commercial leadership experience Two additional industry veterans join in key roles incl
ENDRA Life Sciences has appointed Alexander Tokman as acting CEO following the departure of Francois Michelon. Tokman, who has over 24 years of commercial leadership experience, will spearhead efforts to advance the company’s Thermo Acoustic Enhanced UltraSound (TAEUS) technology. Additionally, Ziad Rouag and Richard Jacroux have been welcomed to the management team, focusing on regulatory affairs and financial strategies, respectively. The company is emphasizing its commitment to bringing innovative diagnostic solutions to the market.
Read more →NDRAENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. announced the pricing of a public offering expected to generate gross proceeds of approximately $8 million. The offering includes 61.5 million shares of common stock and associated warrants, with each share priced at $0.13. The funds raised will be allocated to working capital and general corporate purposes. The offering is anticipated to close on June 5, 2024, pending the satisfaction of customary closing conditions.
Read more →NDRAENDRA Provides Update Following In-person Meeting with FDA Increases clarity for ENDRA on regulatory path forward for TAEUS ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. has provided an update following a productive pre-submission meeting with the FDA about its TAEUS liver device. The meeting discussed the clinical trial design necessary for the U.S. De Novo filing, during which ENDRA showcased the TAEUS procedure. The feedback received is viewed as constructive, allowing ENDRA to refine its pivotal clinical study protocol and statistical plan ahead of submission. Management emphasizes the importance of engagement with the FDA to ensure alignment for their future studies.
Read more →About ENDRA Life Sciences Inc.
Headquarters3600 GREEN COURT, ANN ARBOR, MI, 48105
BIOPHARMAWATCH ELITE PLUS
Trade the next NDRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime